VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Year: 2019
Type: conference-abstract
Source: Blood
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2989534929
